Cargando…

Clinical heterogeneity in patients with myoclonus associated to COVID-19

OBJECTIVE: This study aims to report the clinical heterogeneity of myoclonus in 6 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Patient data were obtained from medical records from the University Hospital Dr. Josep Trueta, Girona, Spain. RESULTS: Six p...

Descripción completa

Detalles Bibliográficos
Autores principales: Álvarez Bravo, Gary, Sánchez Cirera, Laura, Angerri Nadal, Mònica, Ramió i Torrentà, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731181/
https://www.ncbi.nlm.nih.gov/pubmed/34988717
http://dx.doi.org/10.1007/s10072-021-05802-1
_version_ 1784627302566461440
author Álvarez Bravo, Gary
Sánchez Cirera, Laura
Angerri Nadal, Mònica
Ramió i Torrentà, Lluís
author_facet Álvarez Bravo, Gary
Sánchez Cirera, Laura
Angerri Nadal, Mònica
Ramió i Torrentà, Lluís
author_sort Álvarez Bravo, Gary
collection PubMed
description OBJECTIVE: This study aims to report the clinical heterogeneity of myoclonus in 6 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Patient data were obtained from medical records from the University Hospital Dr. Josep Trueta, Girona, Spain. RESULTS: Six patients (5 men and 1 woman, aged 60–76 years) presented with different myoclonus phenotypes. All of them had a medical history of hypertension and overweight. The latency of myoclonus appearance ranged from 1 to 129 days. The phenotype most observed was generalized myoclonus. Special phenotypes such as painful legs and moving toes syndrome with jerking feet, Lazarus sign-like, action myoclonus/ataxia syndrome, and segmental myoclonus secondary to myelitis have been described too. Levetiracetam and clonazepam were medications most used successfully. Two patients died for complications not related to myoclonus. CONCLUSIONS: Our 6 cases highlight the heterogeneity of the clinical spectrum of myoclonus associated to COVID-19 (MYaCO). MYaCO pathogenesis is suspected to be due to an immune-mediated para- or post-infectious phenomenon; nevertheless, further research is needed to elucidate this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-021-05802-1.
format Online
Article
Text
id pubmed-8731181
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87311812022-01-06 Clinical heterogeneity in patients with myoclonus associated to COVID-19 Álvarez Bravo, Gary Sánchez Cirera, Laura Angerri Nadal, Mònica Ramió i Torrentà, Lluís Neurol Sci Covid-19 OBJECTIVE: This study aims to report the clinical heterogeneity of myoclonus in 6 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Patient data were obtained from medical records from the University Hospital Dr. Josep Trueta, Girona, Spain. RESULTS: Six patients (5 men and 1 woman, aged 60–76 years) presented with different myoclonus phenotypes. All of them had a medical history of hypertension and overweight. The latency of myoclonus appearance ranged from 1 to 129 days. The phenotype most observed was generalized myoclonus. Special phenotypes such as painful legs and moving toes syndrome with jerking feet, Lazarus sign-like, action myoclonus/ataxia syndrome, and segmental myoclonus secondary to myelitis have been described too. Levetiracetam and clonazepam were medications most used successfully. Two patients died for complications not related to myoclonus. CONCLUSIONS: Our 6 cases highlight the heterogeneity of the clinical spectrum of myoclonus associated to COVID-19 (MYaCO). MYaCO pathogenesis is suspected to be due to an immune-mediated para- or post-infectious phenomenon; nevertheless, further research is needed to elucidate this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-021-05802-1. Springer International Publishing 2022-01-06 2022 /pmc/articles/PMC8731181/ /pubmed/34988717 http://dx.doi.org/10.1007/s10072-021-05802-1 Text en © Fondazione Società Italiana di Neurologia 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Álvarez Bravo, Gary
Sánchez Cirera, Laura
Angerri Nadal, Mònica
Ramió i Torrentà, Lluís
Clinical heterogeneity in patients with myoclonus associated to COVID-19
title Clinical heterogeneity in patients with myoclonus associated to COVID-19
title_full Clinical heterogeneity in patients with myoclonus associated to COVID-19
title_fullStr Clinical heterogeneity in patients with myoclonus associated to COVID-19
title_full_unstemmed Clinical heterogeneity in patients with myoclonus associated to COVID-19
title_short Clinical heterogeneity in patients with myoclonus associated to COVID-19
title_sort clinical heterogeneity in patients with myoclonus associated to covid-19
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731181/
https://www.ncbi.nlm.nih.gov/pubmed/34988717
http://dx.doi.org/10.1007/s10072-021-05802-1
work_keys_str_mv AT alvarezbravogary clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19
AT sanchezcireralaura clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19
AT angerrinadalmonica clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19
AT ramioitorrentalluis clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19